Company Update (NYSE:MRK): Merck Announces European Medicines Agency Acceptance of Marketing Authorization Application for Grazoprevir/Elbasvir, an Investigational Therapy for Treatment of Chronic Hepatitis C Infection
July 23, 2015 at 11:02 AM EDT
[Business Wire] – Merck , known as MSD outside the United States and Canada, today announced the European Medicines Agency has accepted for review a marketing authorization application for grazoprevir/elbasvir , an investigational, . . . → Read More: Company Update (NYSE:MRK): Merck Announces European Medicines Agency Acceptance of Marketing Authorization Application for Grazoprevir/Elbasvir, an Investigational Therapy for Treatment of Chronic Hepatitis C Infection Similar Articles: Company Update (NYSE:MRK): Merck to Hold Second-Quarter 2015 Sales and Earnings Conference Call on July 28 Company Update: Merck & Co Inc (NYSE:MRK) – Merck Reaffirms Continued Commitment to Developing Innovative Medicines for the Treatment of Infectious Diseases at 25th Annual ECCMID Congress Company Update (NYSE:MRK): Merck says hepatitis C treatment to lose "breakthrough" status